// App-Quantinova.ai

3635 : CTC and ctDNA profiling to detect 6 NCCN-guideline recommended classes of alterations for immunotherapy and targeted therapy selection using sample from a single blood draw

Researchers

Presenter

  • Huangpin B. Hsieh

Principal Investigators

  • Feng-Ming Lin

  • Julian Lucas

  • Alex Atkins

  • Pratyush Gupta

  • Hung-Jen Shao

  • Yen-Lin Chen

  • Wen-Jie Huang

  • Chia-Hsun Hsieh

  • Ruey Kuen Hsieh

  • Kuo-Wei Chen

  • Ming-Hong Yen

  • Mana Javey

  • Shih-En Chang

  • Twinkal Marfatia

  • Drew Watson

  • Mahul Amin

  • Ashish Nimgaonkar

  • Oscar Segurado

  • Rui Mei

Medical Centers

  • CellMax Life, Sunnyvale, CA

  • Cardinal Tien Hospital, New Taipei, Taiwan

  • Far Eastern Memorial Hospital, New Taipei City, Taiwan

  • Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

  • Far Eastern Memorial Hospital, New Taipei City, Taiwan

  • Cheng Hsin General Hospital, Taipei, Taiwan

  • Cathay General Hospital, Taipei, Taiwan

  • Kit Bio Inc, LOS Altos, CA

  • The University of Tennessee Health Science Center, Memphis, TN

  • The Johns Hopkins Hospital, Baltimore, MD

  • Medic Affairs Consulting LLC, San Jose, CA

Locations

  • United States

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • BAT-25

  • BAT-26

  • Circulating tumor cells

  • Programmed death-ligand 1

  • Epithelial Cell Adhesion Molecule

  • Transcription factor Maf

  • Microsatellite instability

  • Circulating DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved